Clinical Trial

proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2

Study acronym: MERCURI-2
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Multi-centre, triple-blinded (patients, physicians, investigators), parallel-group, balanced (1:1), stratified (sex, type 2 diabetes mellitus), randomized, controlled (placebo), phase IV clinical trial to investigate the potential of preoperative initiation (from day 1 before surgery) and perioperative continuation (until day 2 after surgery) of the SGLT2 inhibitor dapagliflozin 10 mg once daily to prevent AKI according to the KDIGO criteria (an increase in serum creatinine by 0.3 mg/dl (26.5 mmol/l) within 48 hours; or an increase in serum creatinine to 1.5 times baseline, within 7 days; or a urine output \<0.5 ml/kg/h for \>6 hours) in adult (\>18 years old) patients undergoing cardiopulmonary bypass surgery.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-10-18; most recent amendment 2025-05-14.
Status change: Recruiting → Active, Not Recruiting 2025-05-14
Status change: Not Yet Recruiting → Recruiting 2023-06-23
Trial Details
NCT Number NCT05590143
Lead Sponsor Amsterdam UMC
Collaborators: ZonMw: The Netherlands Organisation for Health Research and Development
Conditions Acute Kidney Injury, Cardiac Surgery, Sodium-Glucose Transporter 2 Inhibitor
Enrollment 784 participants
Start Date 2023-06-09
Primary Completion 2025-05-14 (estimated)
Study Completion 2025-09 (estimated)
Updated on ClinicalTrials.gov 2025-05-18